Eisai to Present Real-World Lecanemab Data at AD/PD™ 2026
Event summary
- Eisai will present real-world data on lecanemab (LEQEMBI®) at the AD/PD™ 2026 conference in Copenhagen, March 17-21.
- Presentations will include long-term treatment persistence data, safety/efficacy in ApoEε4 homozygous carriers, and four-year data from the Clarity AD Open-Label Extension trial.
- Eisai is sponsoring a symposium focused on early intervention in Alzheimer's disease, featuring four global experts.
- Lecanemab has been approved in 53 countries and regions, with applications pending in 6 more, and a subcutaneous formulation BLA accepted in China in January 2026.
The big picture
The presentation of real-world data on lecanemab is a critical step in validating its clinical and commercial potential within the rapidly evolving Alzheimer's treatment landscape. The focus on early intervention and real-world outcomes reflects a broader industry shift towards proactive disease management and a recognition of the limitations of traditional clinical trials. Eisai’s collaboration with Biogen and BioArctic underscores the complexity of bringing novel therapies to market in this space, requiring significant investment and shared risk.
What we're watching
- Commercial Adoption
- The real-world persistence data will be crucial in assessing the long-term commercial viability of lecanemab, particularly given the ongoing debate around its efficacy and cost.
- Regulatory Landscape
- The acceptance of the subcutaneous formulation BLA in China and Japan, coupled with the Priority Review for the initiation treatment in the US, will indicate the regulatory appetite for expanded access and delivery methods.
- Partner Dynamics
- Eisai's continued leadership role in lecanemab development and regulatory submissions, despite co-commercialization with Biogen, will be a key indicator of the evolving partnership structure.
Related topics